Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

PatrickandFrankie Sep. 22 at 7:20 PM

$PSNL and here we are still trading slightly above the acquisition price while we should normally be trading below.. why would anyone be buying above the acquisition price I wonder ?

0 · Reply

Wax_Bean_futures Sep. 21 at 4:49 PM

$PSNL my only holding that's red today 😡😖🤬🤬🤬🤬

0 · Reply

arribaStocktrading Sep. 21 at 3:15 PM

$PSNL Just staying awake now takes real skill.

1 · Reply

PatrickandFrankie Sep. 20 at 8:52 PM

$PSNL I can’t wait to vote no!

1 · Reply

Wax_Bean_futures Sep. 18 at 7:13 PM

$PSNL 5 cents over deal price. Sell sell sell!!

0 · Reply

SelfMafia Sep. 18 at 1:54 AM

$MRK $MRNA $PSNL $TEM $XBI TEM UP 52% SINCE POST…TEM GOING TO $90+

0 · Reply

NeverFadeTheOracle Sep. 18 at 1:37 AM

$SDGR Thought she was left for dead. But then you look at $PSNL And $ABSI $PSNL and realize $TEM trying to make waves

1 · Reply

LucienW Sep. 17 at 8:16 PM

$PSNL 1m+ shares traded after hours. Any news? I didn’t find any

1 · Reply

MD109 Sep. 17 at 4:03 PM

$PSNL $TEM

1 · Reply

arribaStocktrading Sep. 17 at 2:13 PM

$PSNL "CEO spotlights major test pricing upside at Morgan Stanley conference, driving $TEM rally". Eric will be remembered as the G.O.A.T. of dealmaking if he can stick the landing @ 16.25. And, oh by the way, did I not say that $TEM was going to $80?

1 · Reply

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

BZH HOWL MKTX

2026-09-01T09:20:29.000Z - 22 days ago

Tempus AI upgraded to Overweight from Neutral at Piper Sandler

TEM

2026-08-24T13:00:29.000Z - 4 weeks ago

Personalis downgraded to Hold from Buy at Craig-Hallum

2026-08-04T20:12:18.000Z - 7 weeks ago

Personalis reports Q2 EPS (30c), consensus (28c)

2026-08-04T20:11:59.000Z - 7 weeks ago

Personalis says not providing guidance or conducting earnings call

TEM

Aug 4, 2026, 4:01 PM EDT - 7 weeks ago

Personalis Reports Second Quarter Results and Recent Highlights

Aug 4, 2026, 4:00 PM EDT - 7 weeks ago

Personalis Earnings release: Q2 2026

Aug 4, 2026, 4:00 PM EDT - 7 weeks ago

Personalis Quarterly report: Q2 2026

Jul 29, 2026, 9:39 PM EDT - 7 weeks ago

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

FNWD

Jul 27, 2026, 10:22 AM EDT - 1 month ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

LXFR

Jul 21, 2026, 10:46 AM EDT - 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

NUVL

2026-07-21T10:41:24.000Z - 2 months ago

Personalis price target raised to $16.25 from $11 at BTIG

TEM

2026-07-20T20:18:32.000Z - 2 months ago

Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”

TEM

2026-07-20T18:45:13.000Z - 2 months ago

Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles

TEM

2026-07-20T18:20:22.000Z - 2 months ago

AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B

AMTM GOOG GOOGL NVDA QMLS TEM XMTR

2026-07-20T16:00:42.000Z - 2 months ago

Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis

AAPL ACHR AER AMC BA BABA BAM

2026-07-20T15:40:12.000Z - 2 months ago

Personalis downgraded to Hold from Buy at Needham

Jul 20, 2026, 10:44 AM EDT - 2 months ago

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

TEM

2026-07-20T14:10:32.000Z - 2 months ago

Personalis downgraded to Hold from Buy at Lake Street

TEM

2026-07-20T12:55:07.000Z - 2 months ago

Personalis trading resumes

Jul 20, 2026, 8:44 AM EDT - 2 months ago

Tempus to acquire Personalis for $1.5 billion

TEM

2026-07-20T12:35:54.000Z - 2 months ago

Tempus AI to acquire Personalis for $16.25 per share

TEM

2026-07-20T12:35:19.000Z - 2 months ago

Tempus AI to acquire Personalis for $16.25 per share

TEM

Jul 20, 2026, 8:30 AM EDT - 2 months ago

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

TEM

2026-07-20T12:25:09.000Z - 2 months ago

Personalis trading halted, news pending

2026-07-17T11:20:50.000Z - 2 months ago

Personalis price target raised to $17 from $12 at Needham

MRK TEM

2026-07-16T19:35:24.000Z - 2 months ago

Personalis attracting takeover interest, Street Insider says

MRK

2026-07-16T19:35:17.000Z - 2 months ago

Personalis moves off low after blog claims company exploring possible sale

2026-07-15T12:56:09.000Z - 2 months ago

Personalis price target raised to $18 from $10 at TD Cowen

Jul 14, 2026, 6:00 AM EDT - 2 months ago

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Jun 9, 2026, 6:00 AM EDT - 3 months ago

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Jun 2, 2026, 6:00 AM EDT - 3 months ago

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

May 26, 2026, 6:00 AM EDT - 4 months ago

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 20, 2026, 6:00 AM EDT - 4 months ago

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 14, 2026, 4:01 PM EDT - 4 months ago

Personalis to Participate in Upcoming Investor Events

May 13, 2026, 6:00 AM EDT - 4 months ago

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 12, 2026, 12:00 PM EDT - 4 months ago

Personalis Transcript: AGM 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Personalis Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Personalis Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 4 months ago

Personalis Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 4 months ago

Personalis Reports First Quarter Results and Recent Highlights

Apr 23, 2026, 4:01 PM EDT - 5 months ago

Personalis to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 6:00 AM EDT - 5 months ago

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Apr 13, 2026, 6:00 AM EDT - 5 months ago

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Personalis Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Personalis Proxy statement: Proxy filing

Apr 1, 2026, 4:01 PM EDT - 5 months ago

Personalis to Participate in the 25th Annual Needham Virtual Conference

Mar 17, 2026, 4:00 PM EDT - 6 months ago

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Mar 12, 2026, 6:00 AM EDT - 6 months ago

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Personalis Earnings release: Q4 2025

Feb 26, 2026, 4:01 PM EST - 6 months ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 17, 2026, 4:01 PM EST - 7 months ago

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Feb 12, 2026, 4:01 PM EST - 7 months ago

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 6:00 AM EST - 7 months ago

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

Feb 2, 2026, 6:00 AM EST - 7 months ago

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Jan 28, 2026, 4:01 PM EST - 7 months ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 12, 2026, 4:00 PM EST - 8 months ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Jan 8, 2026, 8:00 AM EST - 8 months ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dec 17, 2025, 6:00 AM EST - 9 months ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 11, 2025, 9:00 AM EST - 9 months ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Nov 18, 2025, 4:01 PM EST - 10 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Personalis Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 11 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 11 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 1 year ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 1 year ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 1 year ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate in Upcoming Investor Conferences

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 1 year ago

Personalis Quarterly report: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 1 year ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

PatrickandFrankie Sep. 22 at 7:20 PM

$PSNL and here we are still trading slightly above the acquisition price while we should normally be trading below.. why would anyone be buying above the acquisition price I wonder ?

0 · Reply

Wax_Bean_futures Sep. 21 at 4:49 PM

$PSNL my only holding that's red today 😡😖🤬🤬🤬🤬

0 · Reply

arribaStocktrading Sep. 21 at 3:15 PM

$PSNL Just staying awake now takes real skill.

1 · Reply

PatrickandFrankie Sep. 20 at 8:52 PM

$PSNL I can’t wait to vote no!

1 · Reply

Wax_Bean_futures Sep. 18 at 7:13 PM

$PSNL 5 cents over deal price. Sell sell sell!!

0 · Reply

SelfMafia Sep. 18 at 1:54 AM

$MRK $MRNA $PSNL $TEM $XBI TEM UP 52% SINCE POST…TEM GOING TO $90+

0 · Reply

NeverFadeTheOracle Sep. 18 at 1:37 AM

$SDGR Thought she was left for dead. But then you look at $PSNL And $ABSI $PSNL and realize $TEM trying to make waves

1 · Reply

LucienW Sep. 17 at 8:16 PM

$PSNL 1m+ shares traded after hours. Any news? I didn’t find any

1 · Reply

MD109 Sep. 17 at 4:03 PM

$PSNL $TEM

1 · Reply

arribaStocktrading Sep. 17 at 2:13 PM

1 · Reply

Wax_Bean_futures Sep. 17 at 2:11 PM

$PSNL is there a way to not just simply vote no, but fuck no? 🤔 Is TEM going to be over 100 by the time the deal goes through? $125 $150

0 · Reply

Enjoyycall Sep. 17 at 12:26 PM

$PSNL Here we are…trade accordingly. Nothing new under the sun.

1 · Reply

Wax_Bean_futures Sep. 15 at 8:02 PM

$PSNL balls, balls, balls, crap, shit and also balls. Did I mention balls? Oh yeah balls P.S. BALLS!!!!!!!

1 · Reply

Wax_Bean_futures Sep. 15 at 2:08 PM

$PSNL yep, it's over. Just give me my fucking $16.25 now 😆

2 · Reply

LucienW Sep. 11 at 3:29 PM

$PSNL it’s interesting how the merger is affecting both $TEM and $PSNL in a negative manner. If the market knows for sure if the deal is/isn’t going to close, at least one of them should be performing nicely. But now, both are craps.

2 · Reply

BeeDecay Sep. 11 at 2:33 PM

$PSNL ✅

1 · Reply

arribaStocktrading Sep. 11 at 2:25 PM

$PSNL *Chime* "You have arrived at your destination"

0 · Reply

Universaal Sep. 10 at 7:17 PM

$VSTM told you all to sell $XERS two days ago $PSNL

0 · Reply

Wax_Bean_futures Sep. 10 at 12:25 PM

$PSNL $16.27 pre-market. Oh well, Guess the deal is set in stone. So be it. Hope $TEM goes to $500 in the next few years

1 · Reply

Universaal Sep. 9 at 6:33 PM

$XERS $VSTM $PSNL highly overpriced overbought zones entire biotech needs a huge correction

3 · Reply

Gallium7 Sep. 8 at 10:09 PM

$PSNL https://beincrypto.com/cancer-vaccine-diagnostics-investment-opportunity/

0 · Reply

Gallium7 Sep. 8 at 10:06 PM

$PSNL https://www.foxbusiness.com/video/6404780967112

0 · Reply

Market Cap	1.70B
Revenue (ttm)	69.65M
Net Income (ttm)	-81.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-116.68%
Debt to Equity Ratio	0.00

Volume	1,369,300
Avg Vol	3,764,020
Day's Range	N/A - N/A
Shares Out	104.72M
Stochastic %K	67%
Beta	2.31
Analysts	Sell
Price Target	$15.44